NOVEL APPROACHES TO ADDRESS RESISTANCE TO ANTI PD-1/PD-L1 THERAPY IN NSCLC

被引：0
|
作者：
Sehgal, M. [1 ]
Das, N. [1 ]
Thekkadath, R. [1 ]
Mittal, N. [1 ]
Chauhan, U. [1 ]
Eswaran, S. [1 ]
机构：
[1] COURSE5 Intelligence Pvt Ltd, Bengaluru, KA, India
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN46
引用
收藏
页码：S444 / S444
页数：1
相关论文
共 50 条
  • [21] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    LABORATORY INVESTIGATION, 2015, 95 : 123A - 123A
  • [22] PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
    Inoue, Yusuke
    Osman, Murat
    Suda, Takafumi
    Sugimura, Haruhiko
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S199 - S202
  • [23] Chemotherapy thorn PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC
    Hendriks, Lizza E. L.
    Remon, Jordi
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 499 - 502
  • [24] PD-1/PD-L1 inhibitor use for NSCLC: more irAEs with first-line therapy
    Reactions Weekly, 2023, 1980 (1) : 10 - 10
  • [25] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [26] PD-1/PD-L1/CTLA-4 INHIBITOR THERAPY FOLLOWING PROGRESSION ON A DIFFERENT PD-1/PD-L1 INHIBITOR: A CASE SERIES
    Mukkamala, Suresh
    Tawagi, Karine
    Matrana, Marc
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A121 - A121
  • [27] Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Shergold, Amy L.
    Millar, Rhona
    Nibbs, Robert J. B.
    PHARMACOLOGICAL RESEARCH, 2019, 145
  • [28] Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
    Cheng, Chao
    Zhuge, Lingdun
    Xiao, Xin
    Luan, Siyuan
    Yuan, Yong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Katerina Ancevski Hunter
    Mark A. Socinski
    Liza C. Villaruz
    Molecular Diagnosis & Therapy, 2018, 22 : 1 - 10
  • [30] Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
    Mengling Wu
    Qianrui Huang
    Yao Xie
    Xuyi Wu
    Hongbo Ma
    Yiwen Zhang
    Yong Xia
    Journal of Hematology & Oncology, 15
12345